Introduction
Drug development increasingly depends on quantitative evidence to guide decisions on dosing, efficacy, safety and clinical trial design. The challenge is not simply generating more data but demonstrating that the evidence is reliable and appropriate for the decision it supports.
The final ICH M15 guidelines, adopted in January 2026, and the US FDA’s final M15 guidance, issued in June 2026, mark an important step towards harmonising how model-informed evidence is planned, evaluated and documented. For pharmaceutical companies, this creates a clearer framework for integrating modelling into development strategies and eCTD regulatory submissions.
What is Model-Informed Drug Development (MIDD)?
Model-informed drug development (MIDD) uses computational modelling and simulation to integrate nonclinical data, clinical findings, prior knowledge and drug or disease characteristics. These methods help predict outcomes, evaluate uncertainty and inform development decisions.
Applications include population pharmacokinetics, exposure-response analysis, physiologically based pharmacokinetic modelling, disease progression modelling and quantitative systems pharmacology. Depending on the question, MIDD can support dose selection, trial design, safety evaluation and decisions for specific patient populations.
Understanding the ICH M15 Guideline
The ICH M15 guideline establishes harmonised principles for assessing evidence generated through MIDD. It focuses on defining the question of interest, establishing the model’s context of use, evaluating model risk and impact, and documenting the resulting evidence.
A central feature is the assessment framework, which considers how much a model influences a decision and the potential consequences of an incorrect decision. This risk-based approach helps determine the extent of model evaluation needed.
The guideline also emphasises model verification, validation, applicability assessment and structured reporting through a Model Analysis Plan (MAP) and Model Analysis Report (MAR), where appropriate. It complements existing topic-specific ICH guidelines rather than replacing them.
Understanding the FDA MIDD Framework
The FDA’s approach combines scientific assessment principles with opportunities for early regulatory engagement. Its MIDD Paired Meeting Program enables eligible drug developers to discuss proposed modelling strategies with FDA reviewers and obtain feedback on specific development questions.
The programme prioritises areas such as dose selection, clinical trial simulation and predictive or mechanistic safety evaluation. The final M15 guidance now provides a harmonised basis for planning and presenting MIDD evidence in these interactions and in regulatory submission services.
Importantly, a meeting does not automatically qualify a model for every future application or guarantee regulatory acceptance. The proposed approach must remain appropriate for its intended use and supported by sufficient evidence.
ICH M15 vs. FDA MIDD Framework: Key Differences and Alignment
ICH M15 and the FDA MIDD framework serve related but distinct purposes.
- ICH M15 guideline: Establishes general principles for planning, evaluating, reporting and submitting MIDD evidence across the ICH regions.
- FDA MIDD framework: Applies these scientific principles within the US regulatory context, including opportunities for programme-specific discussions through the MIDD Paired Meeting Program.
Their alignment encourages consistent terminology, transparent assessment and clearer communication between sponsors and regulators. However, implementation and regulatory interactions remain subject to applicable regional requirements.
How ICH M15 and the FDA MIDD Framework Are Changing Evidence Generation
The key shift is towards evidence that is not only scientifically sound but also transparently justified for a specific regulatory decision. Model development, risk assessment and documentation become connected activities rather than separate technical exercises.
Sponsors can plan earlier for the data needed to build and evaluate models, explain their limitations and demonstrate how model outputs contribute to the overall evidence package. This can improve the clarity of regulatory discussions and reduce avoidable uncertainty, although it does not guarantee shorter development timelines or approval.
Key Applications of MIDD Across the Drug Development Lifecycle
MIDD can support several stages of pharmaceutical development:
- Early development: Inform first-in-human dose selection using nonclinical and pharmacological evidence.
- Clinical development: Support dose optimisation, exposure-response assessment and trial simulation.
- Special populations: Evaluate dosing considerations where dedicated clinical studies may be difficult or limited.
- Safety assessment: Investigate exposure-related risks and support mechanistic safety evaluations.
- Regulatory submissions: Present model assumptions, performance, limitations and conclusions in a structured, reviewable format.
The appropriate application depends on the model, available data, intended context of use and potential consequences of an incorrect decision.
Benefits of Aligning MIDD Strategies with Regulatory Expectations
Aligning MIDD strategies with ICH M15 and applicable FDA expectations can improve scientific transparency, strengthen evidence traceability and support more focused regulatory discussions. It also helps multidisciplinary teams understand how modelling contributes to benefit–risk assessment and development decisions.
The greatest value comes from integrating modelling into the development plan early, rather than preparing the justification only when a submission is approaching.
Challenges in Implementing ICH M15 and MIDD Strategies
Implementation requires more than selecting an appropriate modelling technique. Sponsors must address data quality, model assumptions, uncertainty, applicability and the consequences of relying on an incorrect prediction.
Other challenges include coordinating clinical, pharmacology, statistics and regulatory teams, maintaining consistent documentation, and explaining complex results in a way that supports regulatory assessment. The level of evidence and evaluation should be proportionate to the model’s intended influence and associated risk.
How Pharmaceutical Companies Can Prepare for ICH M15
Pharmaceutical companies should begin by identifying the development decisions that MIDD is intended to support. They can then define the context of use, assess model influence and risk, establish verification and validation plans, and document assumptions and limitations.
Preparing a Model Analysis Plan, maintaining a clear record of model development and results, and engaging regulators early when appropriate can strengthen the overall strategy. Companies should also review existing modelling practices against the final guideline and applicable regional requirements.
What ICH M15 Means for the Future of Drug Development
The ICH M15 guideline represents a move towards more consistent, risk-based evaluation of model-generated evidence. Together with the FDA MIDD framework, it reinforces the importance of scientific credibility, transparent documentation and early alignment with regulatory expectations.
For pharmaceutical companies, the opportunity lies in using modelling not merely to generate predictions, but to build defensible evidence that supports development decisions. DDReg can support organisations through regulatory strategy, scientific and regulatory documentation, and interpretation of evolving global requirements, helping teams connect evidence-generation plans with submission expectations.
As MIDD becomes more integrated into drug development, the ability to explain why a model is suitable, how its limitations are managed and what its results mean for a regulatory decision will remain essential.